• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Bevacizumab: Antiangiogenic cancer therapy.
【24h】

Bevacizumab: Antiangiogenic cancer therapy.

机译：贝伐单抗：抗血管生成癌治疗。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Angiogenesis, the process of new blood vessel formation, is an essential step in tumor growth and metastasis. Vascular endothelial growth factor (VEGF) is a key mediator in this process, and elevated levels of this cytokine are observed in solid tumors and are correlated with worse clinical outcomes. Research has therefore focused on developing agents that target angiogenic factors such as VEGF in order to inhibit tumor growth. One such agent is bevacizumab, a humanized monoclonal antibody generated by engineering the VEGF-binding residues of a murine neutralizing antibody into the framework of a normal human immunoglobulin G. Bevacizumab recognizes VEGF receptors 1 and 2 and thus can neutralize the biologically active forms of VEGF that interact with these receptors. In addition, bevacizumab has shown antiangiogenic and antitumor activity in several cancer types, recently gaining approval from the FDA for use in combination with fluorouracil-based chemotherapy as a first-line treatment for metastatic cancer of the colon or rectum. (c) 2005 Prous Science. All rights reserved.
机译：血管生成是新血管形成的过程，是肿瘤生长和转移的重要步骤。血管内皮生长因子（VEGF）是该过程的关键介体，在实体瘤中观察到该细胞因子水平升高，并且与较差的临床结果相关。因此，研究集中在开发靶向血管生成因子（例如VEGF）以抑制肿瘤生长的药物。一种这样的药剂是贝伐单抗，贝伐单抗是通过将鼠中和抗体的VEGF结合残基改造到正常人免疫球蛋白G的框架中而产生的人源化单克隆抗体。贝伐单抗识别VEGF受体1和2，因此可以中和VEGF的生物活性形式。与这些受体相互作用。此外，贝伐单抗在几种癌症类型中均显示出抗血管生成和抗肿瘤活性，最近获得了FDA的批准，可与基于氟尿嘧啶的化学疗法联用，作为结肠或直肠转移性癌症的一线治疗药物。 （c）2005 Prous科学。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号